1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
Jeffrey S. Weber, Takashi Muramatsu, Omid Hamid, J. Mehnert, F. Stephen Hodi, Swathi Krishnarajapet, Saundra Malatyali, Elizabeth I. Buchbinder, Judith D. Goldberg, Ryan J. Sullivan, Mark B. Faries, Inderjit Mehmi
Topics & Concepts
MedicineIpilimumabNivolumabMetastatic melanomaTocilizumabOncologyInternal medicinePhases of clinical researchClinical trialImmunotherapyCancerDiseaseCancer Immunotherapy and BiomarkersCAR-T cell therapy researchColorectal Cancer Treatments and Studies